Evidence map›Paper›PMID 31762938›Full record

ArticleOncotarget2019

The growth of a xenograft breast cancer tumor model with engineered hyaluronan-accumulating stroma is dependent on hyaluronan and independent of CD44.

Chunmei Zhao, Benjamin J Thompson, Kelly Chen, Feng Gao, Barbara Blouw, Mathieu Marella, Susan Zimmerman, Trevor Kimbler, Sheryl Garrovillo, Jesse Bahn and 6 more

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncotarget, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.9field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 11 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 1 institution in 1 country.

Chunmei ZhaoHalozyme Therapeutics, Inc., San Diego, CA, 92121, USA.
Benjamin J ThompsonHalozyme Therapeutics, Inc., San Diego, CA, 92121, USA.
Kelly ChenHalozyme Therapeutics, Inc., San Diego, CA, 92121, USA.
Feng GaoHalozyme Therapeutics, Inc., San Diego, CA, 92121, USA.
Barbara BlouwHalozyme Therapeutics, Inc., San Diego, CA, 92121, USA.
Mathieu MarellaHalozyme Therapeutics, Inc., San Diego, CA, 92121, USA.
Susan ZimmermanHalozyme Therapeutics, Inc., San Diego, CA, 92121, USA.
Trevor KimblerHalozyme Therapeutics, Inc., San Diego, CA, 92121, USA.
Sheryl GarrovilloHalozyme Therapeutics, Inc., San Diego, CA, 92121, USA.
Jesse BahnHalozyme Therapeutics, Inc., San Diego, CA, 92121, USA.
Lei HuangHalozyme Therapeutics, Inc., San Diego, CA, 92121, USA.
Zhongdong HuangHalozyme Therapeutics, Inc., San Diego, CA, 92121, USA.
H Michael ShepardHalozyme Therapeutics, Inc., San Diego, CA, 92121, USA.
Sanna RosengrenHalozyme Therapeutics, Inc., San Diego, CA, 92121, USA.
Christopher D ThanosHalozyme Therapeutics, Inc., San Diego, CA, 92121, USA.
Daniel C ManevalHalozyme Therapeutics, Inc., San Diego, CA, 92121, USA.
Halozyme Therapeutics (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hyaluronan accumulation in the tumor microenvironment is associated with poor prognosis in several solid human cancers. To understand the role of stromal hyaluronan in tumor progression, we engineered 3T3HAS3, a hyaluronan-producing fibroblast cell line, by lentiviral transduction of Balb/c 3T3 cells with the

Indexed as

breast cancerCD44hyaluronantumor microenvironmentxenograft

Identifiers

PMID31762938
PMCPMC6859925
OpenAlexW2992659726

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.